Effect of Metformin on Frailty in 12 Subjects

Mayo Clinic

Status and phase

Terminated

Phase 2

Conditions

Aging

Inflammation

Frailty

Treatments

Drug: Placebo

Drug: Metformin

Study type

Interventional

Funder types

Other

Identifiers

NCT03451006

17-003088

Details and patient eligibility

About

This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.

Full description

Heart disease is the number one cause of death in the United States and disproportionately affects older adults, underscoring the need to examine determinants of survivorship. Recognizing this gap, current guidelines lay emphasis to assess frailty, a key construct prevalent in elderly and known to impact their prognosis.Older persons are commonly frail, manifest hyperglycemia and their health span is truncated by illnesses during which physiological declines together with accumulation of additional deficits results in multimorbidity and functional dependence. High incidence of functional decline and stress hyperglycemia in patients with coronary artery disease (CAD) makes pharmacologic manipulation, an attractive strategy to improve frailty and reduce adverse cardiovascular outcomes. Metformin exerts its effect on health span as a calorie restriction-mimetic through inhibition of mitochondrial complex 1 and activation of activated protein kinase (AMP).This drug is safe and has been shown to prolong life in mammals. Metformin by reducing effects of cellular senescence and improving glycemic control may improve the functioning of older adults.

In CAD, cellular senescence and inflammation affect organ dysfunction through interference with tissue homeostasis and regeneration. The deleterious effect of senescence includes pro-inflammatory senescence-associated secretory phenotype (SASP). Normal biological function through alteration in cellular homeostasis and restoration of glycemic control may be achieved by metformin. The phenotypic manifestations of these changes are incompletely characterized as it is yet unknown whether cell-intrinsic regenerative mechanisms can be translated into clinical improvement in physical performance and whether it's chronic administration is safe in older adults. These major gaps in knowledge hinder utilization of metformin as an agent to promote cellular regeneration and to reduce the impact of cellular senescence.

Targeting frail individuals with high levels of inflammation and SASP factors would necessitate identification of predictors of improvement with metformin in tissue inflammation and function. A clinomics approach implementing simultaneous assessment of clinical impact coupled with serological profiling would provide enhanced understanding of the local and systemic impact mediated by metformin. Through correlation of molecular profiles with phenotypic expression changes, as proposed herein, investigators will enhance understanding of the regenerative impact of metformin and the basis for clinical improvement in the setting of senescence.

Enrollment

7 patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 60 years
Stable CAD
Prediabetes (one of the following criteria should be met)
- Fasting plasma glucose: 100-126 mg/dL
- HbA1C: 5.7-6.4
Frailty (Short Physical Performance Battery: Score <9)
Able to return for follow-up
Written informed consent

Exclusion criteria

Pre-existing or new-onset diabetes
Any active malignancy, hematological disorder, post organ transplant, immunocompromised
Cancer requiring treatment in the past 3 years (other than non-melanoma skin cancer)
Dementia [mini mental state examination (MMSE <20)]
Disability (need for assistance in >2 of any six activities on Katz activities of daily living (ADL)46
Prior stroke with disability
Acute coronary syndrome <3months or participating in cardiac rehabilitation
Severe Parkinson's
Hepatic insufficiency and/or chronic liver disease (cirrhosis)
Chronic kidney disease (GFR < 45 mL/min)
Taking metformin for any indication
Acute alcohol intoxication
Known hypersensitivity to metformin hydrochloride
Acute/chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma